The place of gliclazide MB in modern treatment strategies for patients with type 2 diabetes mellitus
N. A. Petunina,
N. S. Martirosian,
E. V. Goncharova,
M. E. Telnova,
I. A. Kuzina,
A. O. Shchetinina,
E. A. Elmurzaeva https://doi.org/10.14341/DM13184
Abstract
Sulfonylurea (SU) are an effective class of oral hypoglycemic drugs that have been used in clinical practice for more than 70 years. Despite the common mechanism of action, members of the class have significant intraclass differences in hypoglycemic activity, safety, and the presence of extrapancreatic effects. This review examines the features of gliclazide modified release (MR), its differences from other representatives of the SU and its place in modern recommendations for the treatment of type 2 diabetes mellitus. Gliclazide MR belongs to the modern 2nd generation SU with high hypoglycemic activity, low risk of hypoglycemia due to reversible binding to the SUR1 receptor and no effect on the Epac2 pathway, generally neutral effect on weight, proven nephroprotective properties and cardiovascular safety, which makes it possible to highlight it among representatives of the SU class. International and national clinical guidelines indicate the place of SU when it is necessary to intensify glucose-lowering therapy and glycemic control in patients with type 2 diabetes mellitus.
About the Authors
N. A. Petunina
I.M. Sechenov First Moscow State Medical University
Russian Federation
Competing Interests:
Russian Federation
Nina A. Petunina - PhD, Professor, Сorr. Member of the RAS.
Moscow
Competing Interests:
Статья подготовлена при информационной поддержке компании «Сервье» (Франция)
N. S. Martirosian
I.M. Sechenov First Moscow State Medical University
Russian Federation
Competing Interests:
Russian Federation
Narine S. Martirosian - PhD.
2/4, Bolshaya Pirogovskaya Street, 119991 Moscow
Competing Interests:
Статья подготовлена при информационной поддержке компании «Сервье» (Франция)
E. V. Goncharova
I.M. Sechenov First Moscow State Medical University
Russian Federation
Competing Interests:
Russian Federation
Ekaterina V. Goncharova - PhD.
Moscow
Competing Interests:
Статья подготовлена при информационной поддержке компании «Сервье» (Франция)
M. E. Telnova
I.M. Sechenov First Moscow State Medical University
Russian Federation
Competing Interests:
Russian Federation
Milena E. Telnova - PhD.
Moscow
Competing Interests:
Статья подготовлена при информационной поддержке компании «Сервье» (Франция)
I. A. Kuzina
I.M. Sechenov First Moscow State Medical University
Russian Federation
Competing Interests:
Russian Federation
Irina A. Kuzina
Moscow
Competing Interests:
Статья подготовлена при информационной поддержке компании «Сервье» (Франция)
A. O. Shchetinina
I.M. Sechenov First Moscow State Medical University
Russian Federation
Competing Interests:
Russian Federation
Anna O. Shchetinina - PhD.
Moscow
Competing Interests:
Статья подготовлена при информационной поддержке компании «Сервье» (Франция)
E. A. Elmurzaeva
I.M. Sechenov First Moscow State Medical University
Russian Federation
Competing Interests:
Russian Federation
Elmira A. Elmurzaeva
Moscow
Competing Interests:
Статья подготовлена при информационной поддержке компании «Сервье» (Франция)
References
1. Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes Mellitus. 2023;26(2):104-123. (In Russ.). doi: https://doi.org/10.14341/DM13035
2. Paul SK, Klein K, Thorsted BL, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100. doi: https://doi.org/10.1186/s12933-015-0260-x
3. Lind M, Imberg H, Coleman RL, et al. Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. Diabetes Care. 2021;44(10):2231–7. doi: https://doi.org/10.2337/dc20-2439
4. Wang H, Cordiner RLM, Huang Y, et al.; Scottish Diabetes Research Network Epidemiology Group. Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study. Diabetes Care. 2023;46(5):967-977. doi: https://doi.org/10.2337/dc22-1238
5. Laiteerapong N, Ham SA, Gao Y, et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care. 2019;42(3):416-426. doi: https://doi.org/10.2337/dc17-1144
6. Petunina NA, Goncharova EV, Kuzina IA, Nedosugova LV. et al. The role of pioglitazone in the fight against insulin resistance, atherosclerosis, cardiovascular disease, and non-alcoholic fatty liver disease. Diabetes mellitus. 2022;25(5):504-513. (In Russ.). doi: https://doi.org/10.14341/DM12859
7. Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AYu. 10th edition. Diabetes mellitus. 2021;24(1S):1-148. (In Russ.) doi: https://doi.org/10.14341/DM13042
8. Qian D, Zhang T, Tan X, et al. Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis. PLoS One. 2018;13(8):e0202563. doi: https://doi.org/10.1371/journal.pone.0202563
9. Huang X, Zhou Y, Tang H, et al. Differential metabolic network construction for personalized medicine: Study of type 2 diabetes mellitus patients’ response to gliclazide-modified-release-treated. J Biomed Inform. 2021;118:103796. doi: https://doi.org/10.1016/j.jbi.2021.103796
10. Sola D, Rossi L, Schianca GP, et al. Sulfonylureas and their use in clinical practice. Arch. Med. Sci. 2015;11(4):840–848. doi: https://doi.org/10.5114/aoms.2015.53304
11. Seino S, Miki T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol. 2003;81(2):133-176. doi: https://doi.org/10.1016/s0079-6107(02)00053-6
12. Petunina NA, Trukhina LV, Goncharova EV. Advantages of Intensified Glycemic Control: Results of ADVANCE and ADVANCE-ON Studies. Effectivnaya farmakoterapiya. 2015;7:12-16. (In Russ.).
13. Sugawara K, Shibasaki T, Takahashi H, Seino S. Structure and functional roles of Epac2 (Rapgef4). Gene. 2016;575(2):577-583. doi: https://doi.org/10.1016/j.gene.2015.09.029
14. Desfaits AC, Serri O, Renier G. Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment. Diabetes Care. 1998;21(4):487-93. doi: https://doi.org/10.2337/diacare.21.4.487
15. Desfaits AC, Serri O, Renier G. Gliclazide reduces the induction of human monocyte adhesion to endothelial cells by glycated albumin. Diabetes, Obes Metab. 1999;1(2):113-120. doi: https://doi.org/10.1046/j.1463-1326.1999.00012.x
16. A Räkel, G Renier, A Roussin, et al. Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(1):127-9. doi: https://doi.org/10.1111/j.1463-1326.2006.00571.x
17. Zu Zhi Fu, Tang Yan, Yu-Ju Chen, Ji Quang Sang. Thromboxane/prostacyclin balance in type II diabetes: Gliclazide effects. Metabolism. 1992;41(5):33-35. doi: https://doi.org/10.1016/0026-0495(92)90092-O
18. Kimura T, Takagi H, Suzuma K, et al. Comparisons between the beneficial effects of different sulphonylurea treatments on ischemia-induced retinal neovascularization. Free Radic Biol Med. 2007;43(3):454-461. doi: https://doi.org/10.1016/j.freeradbiomed.2007.04.030
19. Mkrtumyan AM, Dukhanin AS. ‘Road Map’ of the Drug Diabeton MR. Effectivnaya farmakoterapiya. 2019;15(12):28–38. (In Russ.) doi: https://doi.org/10.33978/2307-3586-2019-15-12-28-38
20. Sena CM, Louro T, Matafome P, et al. Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet. Physiol Res. 2009;58(2):203-209. doi: https://doi.org/10.33549/physiolres.931480
21. Cordiner RLM, Mari A, Tura A, Pearson ER. The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function. J Clin Endocrinol Metab. 2021;106(7):2036-2046. doi: https://doi.org/10.1210/clinem/dgab151
22. Satoh J, Takahashi K, Takizawa Y, et al. Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide. Diabetes Res Clin Pract. 2005;70(3):291-7. doi: https://doi.org/10.1016/j.diabres.2005.04.002
23. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes. 1970;19(2):747-830
24. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49:930-36. doi: https://doi.org/10.1007/s00125-006-0176-9
25. Pantalone KM, Kattan MW, Yu C, et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care. 2010;33:1224-29. doi: https://doi.org/10.2337/dc10-0017
26. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. EurHeart. 1999;20:439-46. doi: https://doi.org/10.1053/euhj.1998.1242
27. Nordin C. The proarrhythmic effect of hypoglycemia: evidence for increased risk from ischemia and bradycardia. Acta Diabetol. 2014;51:5-14. doi: https://doi.org/10.1007/s00592-013-0528-0
28. Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015;3(1):43-51. doi: https://doi.org/10.1016/S2213-8587(14)70213-X
29. Zoungas S, Chalmers J, Kengne AP, et al. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract. 2010;89:126–33. doi: https://doi.org/10.1016/j.diabres.2010.05.012
30. Ida S, Kaneko R, Murata K. Effects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus: a network meta-analysis. Cardiovasc Diabetol. 2018;17:129. doi: https://doi.org/10.1186/s12933-018-0773-1
31. Pirart J, Lauvaux JP, Rey W. Blood sugar and diabetic complications. N Engl J Med. 1978;298(20):1149. doi: https://doi.org/10.1056/NEJM197805182982020
32. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589. doi: https://doi.org/10.1056/NEJMoa0806470
33. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653. doi: https://doi.org/10.1056/NEJMoa052187
34. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572. doi: https://doi.org/10.1056/NEJMoa0802987
35. Mohan V, Khunti K, Chan SP, et al. Management of type 2 diabetes in developing countries: balancing optimal glycaemic control and outcomes with affordability and accessibility to treatment. Diabetes Ther. 2020;11(1):15−35. doi: https://doi.org/10.1007/s13300-019-00733-9
36. Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392-1406. doi: https://doi.org/10.1056/NEJMoa1407963
37. Chalmers J, Woodward M. Observational analyses from ADVANCE and ADVANCE-ON. Diabetes Obes Metab. 2020;22(2):19-32. doi: https://doi.org/10.1111/dom.13894
38. Wong MG, Perkovic V, Chalmers J, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care. 2016;39:694–700. doi: https://doi.org/10.2337/dc15-2322
39. Maloney A, Rosenstock J, Fonseca V. A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. Clin Pharmacol Ther. 2019;105(5):1213-23. doi: https://doi.org/10.1002/cpt.1307
40. Al Sifri S, Basiounny A, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a ran- domised trial. Int J Clin Pract. 2011;65:1132–40. doi: https://doi.org/10.1111/j.1742-1241.2011.02797.x
41. Tayek J. SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics. Diabetes Obes Metab. 2008;10(11):1128-9;1129-30. doi: https://doi.org/10.1111/j.1463-1326.2008.00928.x
42. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004;34(8):535-42. doi: https://doi.org/10.1111/j.1365-2362.2004.01381.x
43. Hassanein M, Al Sifri S, Shaikh S, et al. A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN. Diabetes Res Clin Pract. 2020;163:108154. doi: https://doi.org/10.1016/j.diabres.2020.108154
44. Kalra S, Bahendeka S, Sahay R, et al. Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus — International Task Force. Indian J Endocrinol Metab. 2018;22(1):132-157. doi: https://doi.org/10.4103/ijem.IJEM_556_17
45. Lee YH, Lee CJ, Lee HS, et al. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice. Diabetes Metab. 2015;41(3):208-15. doi: https://doi.org/10.1016/j.diabet.2015.01.004
46. Pearson ER, Starkey BJ, Powell RJ, et al. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet. 2003;362(9392):1275-81. doi: https://doi.org/10.1016/S0140-6736(03)14571-0
47. Roberts A, James J, Dhatariya K; Joint British Diabetes Societies (JBDS) for Inpatient Care. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med. 2018;35(8):1011-1017. doi: https://doi.org/10.1111/dme.13675
48. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925-1966. doi: https://doi.org/10.1007/s00125-022-05787-2
49. Marx N, Federici M, Schütt K, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 202;44(39):4043-4140. doi: https://doi.org/10.1093/eurheartj/ehad192
50. Seino S, Zhang CL, Shibasaki T. Sulfonylurea action re-revisited. J Diabetes Investig. 2010;1(1-2):37-9. doi: https://doi.org/10.1111/j.2040-1124.2010.00014.x
Supplementary files
|
|
1. Figure 1. Mechanism of action of glyclazide MR and other sulfonylurea drugs on β-cells of the pancreas (adapted from S. Selno, 2010) [50]. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(139KB)
|
Indexing metadata ▾ | |
Review
For citations:
Petunina N.A., Martirosian N.S., Goncharova E.V., Telnova M.E., Kuzina I.A., Shchetinina A.O., Elmurzaeva E.A. The place of gliclazide MB in modern treatment strategies for patients with type 2 diabetes mellitus. Diabetes mellitus. 2024;27(4):368-375. (In Russ.) https://doi.org/10.14341/DM13184
Views:
918
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
